Following the recent acquisition of Aesica Pharmaceuticals by Consort Medical, the company is pleased to announce the launch of a new brand identity today to align the companies and communicate the consolidated Consort Medical group.
The combination of Aesica and Bespak enables the Consort Medical group to provide our customers with a single source provider for drug dosage forms and devices. Our customers will now benefit from an unrivalled global offering; allowing us to deliver an exceptional value to the supply chain, from early stage drug dosage form and device development to full commercialisation.
Aesica, as a leading pharmaceutical CDMO, Is renowned for developing and manufacturing both APIs and finished dose forms to the pharmaceutical industry. Whilst Bespak, a global market leader in the development and manufacture of drug delivery devices, provides inhaler, auto-injector and nasal technologies, as well as development and manufacturing services.
The new logo and branding will be adopted across the businesses, creating a more consistent identity for all group companies. The official launch to the market is planned to coincide with CPhI 2015.
The core brand message focuses on delivery of early stage development to full scale manufacturing services that help customers to streamline complex supply chains and, in doing so, accelerate the route of drugs to market, reducing cost and complexity for our partners.
The new logo has been inspired by the ‘joining together’ of the companies – with the three-cornered vertex designed to represent a dynamic company that is at the leading edge of innovation.